Orlando Health
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Orlando Health sits in the top decile of US sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count).
Orlando Health: 21 sponsored US clinical trials, 9 recruiting.
Orlando Health sponsors 21 registered US clinical trials on ClinicalTrials.gov, 9 of them currently recruiting, and 7 completed. 2 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pancreatic Cyst, with 2 trials.
Top-decile sponsor footprint
Orlando Health ranks in the top decile of sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
7 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (70.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
21 total, page 1 of 1
EUS Procedures Using RIVOS™ EUS Access Device
NCT07696572
Randomized Trial of Percutaneous vs. Endoscopic Gallbladder Drainage
NCT07696546
Randomized Trial of Next Generation Fluoroscopy System vs. Conventional Fluoroscopy System in Endoscopy
NCT07594132
Strategic Timing of Endoscopic Interventions in Infected Necrotizing Pancreatitis
NCT07406698
AI for Onsite Cytology Evaluation in Endoscopic Ultrasound
NCT07228689
EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope
NCT06340620
Artificial Intelligence in Endoscopic Ultrasound
NCT06564571
EUS-guided Celiac Plexus Block vs. Sham in Chronic Pancreatitis
NCT06178315
Registry of Patients Undergoing Endoscopic Management of Pancreatic Fluid Collections
NCT06179459
Randomized Trial of EUS-guided Gastrojejunostomy and Surgical Gastrojejunostomy in Gastric Outlet Obstruction
NCT05548114
Evaluation of 3D Printed Myoelectric Prosthetic Devices in Children With Upper Congenital Limb Deficiency
NCT05547308
Timing of Tourniquet Release
NCT06576869
Recurrent Abdominal Pain and Exocrine Pancreatic Insufficiency
NCT04231279
Hospital-acquired Pneumonia Prevention: Intervention, Evaluation & Research
NCT04915898
Tortle Midliner and Intraventricular Hemorrhage
NCT03543046
MiniTightRope Suspensionplasty Compared With LRTI for the Treatment of Basilar Thumb Arthritis
NCT02591368
Needleless Jet Injected (J-Tip) Lidocaine in Children Undergoing Regional Anesthesia Prior to Knee Arthroscopy
NCT02649322
Fibular Fixation in Ankle Fractures:Plate Verses Nail.
NCT02507193
Efficacy of Continuous Infusion Ropivacaine Interscalene Blocks
NCT02462382
Post-Op Rotator Cuff Pain Study With Subacromial Bupivacaine Infusion
NCT01126593
Compliance With Once-Daily Divalproex Extended-Release Tablets (Depakote-ER) Versus Multiple-Daily Dose Valproic Acid Capsules (Depakene) in Epilepsy:
NCT00356018
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
| Phase 4 | 1 |
Where Orlando Health enrollment is open (later-stage tilt)
9 recruiting of 21 indexed (43% open); 7 completed (33%).
Phase mix: 2 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Pancreatic Cyst (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Orlando Health: open-pipeline peers nationwide
Peers matched on 21 registered trials and 43% open enrollment, not the therapeutic-area sidebar.
Orlando Health sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 21 trials (± recruiting share)
- AEterna Zentaris · 21 trials · 0% recruiting
- Amphastar Pharmaceuticals · 21 trials · 5% recruiting
- Apellis Pharmaceuticals · 21 trials · 10% recruiting
- Array Biopharma, now a wholly owned subsidiary of Pfizer · 21 trials · 0% recruiting
Sponsors near 43% open enrollment (± trial volume)
- Alphatec Spine · 43% recruiting · 7 trials
- Clarity Pharmaceuticals · 43% recruiting · 7 trials
- Colorado Center for Reproductive Medicine · 43% recruiting · 7 trials
- David Moss · 43% recruiting · 7 trials
Related
What to do with this Orlando Health page
21 registered trials is a research-attention snapshot, not an endorsement of Orlando Health or any single study.
- 9 of Orlando Health's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Pancreatic Cyst is the condition Orlando Health studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pancreatic Cyst trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Orlando Health pipeline card: 21 registered trials from official public datasets.Report a data error.